The US Food and Drug Administration has granted accelerated approval to Bavencio (avelumab) for the treatment of metastatic Merkel cell carcinoma (MCC)–one of the most deadly skin cancers. Prior to this, there have been no FDA-approved treatment for this deadly cancer.